Chordia Therapeutics
Latest round
- Series C
Last raised
- May 2022
Total raised
- $70M
Investors
- 10
About Chordia Therapeutics
Chordia Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics for oncology and rare genetic disorders, aiming to address critical unmet medical needs in global healthcare markets. Founded in 2017, Chordia Therapeutics Inc. is headquartered in Fujisawa, Japan. The company develops biopharmaceutical solutions targeting specific diseases. The founders, Daisuke Morishita and Yumi Imai, have experience in the biotechnology sector. In June 2024, Chordia Therapeutics Inc.1 million shares at JPY 153 per share within the expected JPY 143-153 range, on the Tokyo Stock Exchange Growth Section. The listing values Chordia Therapeutics Inc.03 billion. Chordia Therapeutics Inc. specializes in innovative biopharmaceutical solutions aimed at addressing unmet medical needs. The company's core offerings include a range of therapeutics designed to target specific diseases, with an emphasis on improving patient outcomes in areas such as oncology and rare genetic disorders. Their flagship products have undergone extensive clinical trials, demonstrating efficacy and safety for patients, and are currently in various stages of commercialization in markets such as Japan, North America, and select regions in Europe. Chordia Therapeutics serves a diverse client base that includes healthcare institutions, specialty pharmacies, and direct consumers, thereby ensuring broad accessibility to their therapeutic solutions. The company is dedicated to advancing healthcare by providing solutions that enhance the quality of life for patients facing challenging health conditions. Chordia Therapeutics generates revenue through a structured model that incorporates both B2B partnerships and direct-to-consumer sales. The company engages with healthcare providers and institutions through licensing agreements and product distribution contracts, enhancing their reach within the pharmaceutical market. Typical transactions involve the provision of therapeutics under specific agreements that outline pricing structures based on volume and delivery schedules. Customers, primarily healthcare providers and pharmacies, are expected to purchase these products at established rates, which reflect the value of the therapeutic innovations offered.
Who invested in Chordia Therapeutics
10 investors across 3 rounds
See all investors in Chordia Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Chordia Therapeutics
Who invested in Chordia Therapeutics?
Chordia Therapeutics has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Chordia Therapeutics raised?
Chordia Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Chordia Therapeutics last raise money?
Chordia Therapeutics's most recent round on record is a Series C, in May 2022.
What does Chordia Therapeutics do?
Chordia Therapeutics is a biotechnology company.
Where is Chordia Therapeutics headquartered?
Chordia Therapeutics is headquartered in Fujisawa-shi, Japan.
Which VCs invest in companies like Chordia Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Chordia Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Chordia Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.